Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

Cavagna, L., Trallero-Araguás, E., Meloni, F., Cavazzana, I., Rojas-Serrano, J., Feist, E., et al. (2019). Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. JOURNAL OF CLINICAL MEDICINE, 8(11) [10.3390/jcm8112013].

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

Scirè, Carlo;Pesci, Alberto
;
Dei, Giulia
;
Pozzi, Maria Rosa
;
2019

Abstract

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
Si
Articolo in rivista - Articolo scientifico
Scientifica
antisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositis
English
Cavagna, L., Trallero-Araguás, E., Meloni, F., Cavazzana, I., Rojas-Serrano, J., Feist, E., et al. (2019). Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. JOURNAL OF CLINICAL MEDICINE, 8(11) [10.3390/jcm8112013].
Cavagna, L; Trallero-Araguás, E; Meloni, F; Cavazzana, I; Rojas-Serrano, J; Feist, E; Zanframundo, G; Morandi, V; Meyer, A; Pereira da Silva, J; Matos Costa, C; Molberg, O; Andersson, H; Codullo, V; Mosca, M; Barsotti, S; Neri, R; Scirè, C; Govoni, M; Furini, F; Lopez-Longo, F; Martinez-Barrio, J; Schneider, U; Lorenz, H; Doria, A; Ghirardello, A; Ortego-Centeno, N; Confalonieri, M; Tomietto, P; Pipitone, N; Rodriguez Cambron, A; Blázquez Cañamero, M; Voll, R; Wendel, S; Scarpato, S; Maurier, F; Limonta, M; Colombelli, P; Giannini, M; Geny, B; Arrigoni, E; Bravi, E; Migliorini, P; Mathieu, A; Piga, M; Drott, U; Delbrueck, C; Bauhammer, J; Cagnotto, G; Vancheri, C; Sambataro, G; De Langhe, E; Sainaghi, P; Monti, C; Gigli Berzolari, F; Romano, M; Bonella, F; Specker, C; Schwarting, A; Villa Blanco, I; Selmi, C; Ceribelli, A; Nuno, L; Mera-Varela, A; Perez Gomez, N; Fusaro, E; Parisi, S; Sinigaglia, L; Del Papa, N; Benucci, M; Cimmino, M; Riccieri, V; Conti, F; Sebastiani, G; Iuliano, A; Emmi, G; Cammelli, D; Sebastiani, M; Manfredi, A; Bachiller-Corral, J; Sifuentes Giraldo, W; Paolazzi, G; Saketkoo, L; Giorgi, R; Salaffi, F; Cifrian, J; Caporali, R; Locatelli, F; Marchioni, E; Pesci, A; Dei, G; Pozzi, M; Claudia, L; Distler, J; Knitza, J; Schett, G; Iannone, F; Fornaro, M; Franceschini, F; Quartuccio, L; Gerli, R; Bartoloni, E; Bellando Randone, S; Zampogna, G; Gonzalez Perez, M; Mejia, M; Vicente, E; Triantafyllias, K; Lopez-Mejias, R; Matucci-Cerinic, M; Selva-O'Callaghan, A; Castañeda, S; Montecucco, C; Gonzalez-Gay, M
File in questo prodotto:
File Dimensione Formato  
10281-262516.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/262516
Citazioni
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 58
Social impact